Video
Choosing a CDMO Partner for Your Late-Stage and Commercial Biologics Programs
Summary: Learn more on considerations for choosing the right CDMO for your late-stage biotherapeutics programs in this interview with Stacey Treichler, Ph.D., Director, Head of Marketing & Strategy, BioModalities, Catalent Biologics.
View Now
Video
The Unique Challenges of Lipid Nanoparticle Development and Manufacturing
Summary: Breaking New Ground: Turning mRNA into an Established Therapeutic Modality (Video 3 of 3 in the mRNA fireside chat series with Catalent’s experts).
View Now
Video
mRNA Development and Manufacturing - CMC challenges and Solutions
Summary: Breaking New Ground: Turning mRNA into an Established Therapeutic Modality (Video 2 of 3 in the mRNA fireside chat series with Catalent’s experts).
View Now
Video
mRNA: A New Option for Vaccines and Therapeutics
Summary: Breaking New Ground: Turning mRNA into an Established Therapeutic Modality (Video 1 of 3 in the mRNA fireside chat series with Catalent’s experts).
View Now
Webinars
Streamlining Process Characterization Toward Successful Validation Campaigns
Summary: In this webinar, we explore the drivers for process characterization and late-phase development including improving process understanding, enhancing robustness, and assurance that it delivers...
View Now
Article
Process Validation: A Critical Step in a Biopharmaceutical Product’s Lifecycle
Summary: Process validation, including process characterization, is a critical step in the successful commercialization of a new biopharmaceutical on its path to commercialization. As the program approaches commercial launch...
View Now
eBook
4 Secrets to Reaching First-in-Human Trials Faster: How to Connect with the Right Outsourcing Partner for More Speed and Less Complexity
Summary: In this ebook, read how matching up with the right partner can help you seize the opportunities and assemble the foundation for a successful first-in-humans study
View Now
Video
Drug Substance Manufacturing
Summary: Catalent's Biologics site in Bloomington, Indiana provides a drug substance manufacturing area that includes production bioreactors ranging from 200 L single-use to 2,500 L stainless steel.
View Now
Podcast
Podcast: Obstacles & Opportunities in Orphan Biologics- From Development to Production and Supply
Summary: In this podcast, experts discuss how to overcome obstacles that span from discovery to launch of orphan drugs as well as discuss the needs of patients and drug developers in orphan biologics development.
View Now
Executive Summary
Developing the Next Big Vaccine Technologies
Summary: The field’s top experts weigh in on the technologies they are working on, including self-amplifying RNA, computer-designed nanoparticles, expanding mRNA processes and...
View Now